UGCG and glycogen storage disease VI: N-Butyldeoxynojirimycin 1 (Miglustat) is applied in the clinic for the treatment ofGaucher disease, where it acts as a glucosylceramide synthase inhibitor.44,55 It also inhibits the three human retaining β-glucosidases,GBA1, GBA2, and GBA3.56 None of these enzymesplays a role in SARS-CoV-2 infections, and their inhibition may leadto adverse effects as well.